OSE Immunotherapeutics

OSE Immunotherapeutics (OSE) is based in Nantes and Paris in France and is listed on the Euronext Paris exchange. It is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: International Biotechnology Trust

Borussia Dortmund – executive interviews

UK equities: A generational opportunity?

Audiovisual

Latest

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

IP Group – executive interview

Georgia Capital in 60 seconds

About Edison

About Edison

Careers

OSE Immunotherapeutics (PAR: OSE)

Latest Insights

OSE Immunotherapeutics — Full Lusvertikimab results reflect potential in UC

OSE Immunotherapeutics — Riding the H124 tailwinds

OSE Immunotherapeutics — Tedopi registrational study commences

OSE Immunotherapeutics — Lusvertikimab shines in Phase II UC trial

Sector

Equity Analyst

Key Management

OSE Immunotherapeutics — One step closer to key data readouts

OSE Immunotherapeutics — Confidence boost with AbbVie partnership

OSE Immunotherapeutics — Encouraging OSE-279 clinical update

OSE Immunotherapeutics — Active year ahead for proprietary programmes

OSE Immunotherapeutics — Timely FR104/VEL-101 update with Phase II plans

OSE Immunotherapeutics — Collaboration bolsters upcoming Tedopi Phase III

OSE Immunotherapeutics – executive interview with Nicolas Poirier, CEO

OSE Immunotherapeutics — Anticipation builds with positive OSE-279 data

OSE Immunotherapeutics — Maintaining momentum after an active H123

OSE Immunotherapeutics — Publication puts Tedopi back in the spotlight

OSE Immunotherapeutics — Grant to weave RNA into R&D platform

OSE Immunotherapeutics — Lusvertikimab progressing on multiple fronts

OSE Immunotherapeutics — US patent to bolster Tedopi’s product portfolio

OSE Immunotherapeutics — New diagnostic test to support Tedopi trial

OSE Immunotherapeutics — Milestones anticipated throughout FY23

OSE Immunotherapeutics — Encouraging safety data for OSE-127

OSE Immunotherapeutics — FDA support received for Tedopi Phase III trial

OSE Immunotherapeutics — Introducing its fifth clinical asset

OSE Immunotherapeutics — €10m funding secures runway to Q323

OSE Immunotherapeutics — OSE-127 encouraging preclinical data in ALL

OSE Immunotherapeutics — OSE-127 Phase II study enrolment completed

OSE Immunotherapeutics — Tedopi remains focus in FY22

OSE Immunotherapeutics — Tedopi clinical data in NSCLC and PDAC

OSE Immunotherapeutics — First patient dosed with FR104/VEL-101

OSE Immunotherapeutics — Steady progress on all fronts

OSE Immunotherapeutics — Transforming into R&D powerhouse

OSE Immunotherapeutics — Solid new details from Step 1 of Tedopi Ph III trial

OSE Immunotherapeutics — Encouraging data from novel preclinical projects

OSE Immunotherapeutics – executive interview

OSE Immunotherapeutics — Positive Tedopi step 1, rethinking its future

OSE Immunotherapeutics — Progress with key R&D assets

OSE Immunotherapeutics — R&D progress triggers milestone payment windfall

OSE Immunotherapeutics — A change of pace with three new clinical trials

OSE Immunotherapeutics — Immunotherapy research engine